A Massachusetts-based pharmaceutical company exceeded its fundraising goals Thursday when it completed its debut on the stock market, collecting approximately $255 million from investors.
Seaport Therapeutics announced it had successfully sold 14.16 million shares at $18 per share in its initial public offering, surpassing the company’s original expectations.
The Boston pharmaceutical firm had initially projected raising up to $212.4 million through the sale of 11.8 million shares, with pricing anticipated between $16 and $18 per share. That original plan would have valued the company at roughly $912 million.
Seaport specializes in creating oral medications targeting depression, anxiety, and additional neuropsychiatric conditions. The company’s primary treatment candidate, known as GlyphAllo, is currently in development as a therapy for major depressive disorder.
The successful stock market launch reflects a broader trend of biotechnology companies returning to public markets following a prolonged period of limited activity through much of 2025. Industry analysts attribute this resurgence to recent interest rate reductions by central banks, which have helped restore investment capital flow, though potential rate increases driven by war-related inflation remain a concern for later this year.
Trading of Seaport shares is anticipated to begin on the Nasdaq exchange using the ticker symbol “SPTX.”
Major financial institutions including Goldman Sachs, J.P. Morgan, and Leerink Partners served as underwriters for the stock offering.
